HOME> product


Sales marketing
Bioactivity SEN177 is a potent glutaminyl cyclase (QPCT) inhibitor with an IC50 of 0.013μM for glutaminyl-peptide cyclotransferase-like (QPCTL). SEN177 has a Ki of 20 nM for human glutaminyl cyclase (hQC). SEN177 greatly reduces the early stages of mutant HTT oligomerisation and reduces the percentage of neurons with Q80 aggregates. SEN177 has the potential for Huntington’s disease research[1].
Name SEN177
CAS 2117405-13-5
Formula C18H19FN6
Molar Mass 338.38
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Meike E W Logtenberg, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat Med [2]. Cecilia Pozzi, et al. The structure of the human glutaminyl cyclase-SEN177 complex indicates routes for developing new potent inhibitors as possible agents for the treatment of neurological disorders. J Biol Inorg Chem. 2018 Dec;23(8):1219-1226. [3]. Maria Jimenez-Sanchez, et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat Chem Biol. 2015 May;11(5):347-354.

About Contact

© 2008-2024 PeptideDB SYSTEM All Rights Reserved